dc.contributor.author | Kamali, Sevil | |
dc.contributor.author | KONICE, Meral | |
dc.contributor.author | Inanc, Murat | |
dc.contributor.author | Tufan, FATİH | |
dc.contributor.author | Gul, Ahmet | |
dc.contributor.author | ERER, Burak | |
dc.contributor.author | OCAL, Lale | |
dc.contributor.author | ARAL, Orhan | |
dc.date.accessioned | 2021-03-05T12:12:42Z | |
dc.date.available | 2021-03-05T12:12:42Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Tufan F., Kamali S., ERER B., Gul A., Inanc M., OCAL L., KONICE M., ARAL O., "Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases", CLINICAL RHEUMATOLOGY, cilt.26, ss.1913-1915, 2007 | |
dc.identifier.issn | 0770-3198 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_ac0fd1cf-8875-4235-be67-474d356b906f | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/114829 | |
dc.identifier.uri | https://doi.org/10.1007/s10067-007-0694-y | |
dc.description.abstract | It is reported that the usage of high-dose intravenous immunoglobulin (HD-IVIG) in systemic autoimmune iseases is associated with various adverse events in a wide range of severity. We aimed to investigate the frequency and profile of adverse events in a group of patients with diffuse connective tissue diseases and Wegener's granulomatosis (WG) who were administrated HD-IVIG for different indications. We recorded the data of 38 patients (25 females and 13 males) aged 38 +/- 15 (12-75) years who were followed up with the diagnosis of systemic autoimmune diseases between 1994 and 2006 according to a predefined protocol. Patients with active disease were treated with HD-IVIG and standard immunosuppressives concomitantly. We evaluated the occurrence of allergy, acute renal failure, thromboembolic events, neutropenia, hemolytic anemia, aseptic meningitis, and vasculitis during infusion therapy of HD-IVIG and in the following 3 weeks. We commenced a total of 130 infusions of HD-IVIG. Patients were administrated 1-12 (3.4 +/- 2.6) infusions of HD-IVIG as needed. Indications for HD-IVIG were unresponsiveness or partial response to standard treatment, severe infections along with disease activity, and severe thrombocytopenia in the preoperative period in 97, 23, and 5% of patients, respectively. Minor adverse events were seen in two patients during HD-IVIG infusions. One patient with WG developed rapidly progressive renal failure during severe disease flare between HD-IVIG infusions. Another patient with WG developed recurrence of deep-vein thrombosis during severe disease flare 3 months after HD-IVIG. Both events were attributed to severe disease activity. Adverse events like allergy, acute renal failure, thromboembolic events, hematological problems, aseptic meningitis, and vasculitis are reported in different frequencies (1-81%) in patients who were administered HD-IVIG for systemic autoimmune diseases. HD-IVIG is considered a safe treatment in selected patients assuring adequate infusion precautions. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ROMATOLOJİ | |
dc.title | Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases | |
dc.type | Makale | |
dc.relation.journal | CLINICAL RHEUMATOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 26 | |
dc.identifier.issue | 11 | |
dc.identifier.startpage | 1913 | |
dc.identifier.endpage | 1915 | |
dc.contributor.firstauthorID | 94731 | |